ES2149177T3 - Composiciones para el tratamiento del sindrome de fatiga cronica. - Google Patents

Composiciones para el tratamiento del sindrome de fatiga cronica.

Info

Publication number
ES2149177T3
ES2149177T3 ES92912694T ES92912694T ES2149177T3 ES 2149177 T3 ES2149177 T3 ES 2149177T3 ES 92912694 T ES92912694 T ES 92912694T ES 92912694 T ES92912694 T ES 92912694T ES 2149177 T3 ES2149177 T3 ES 2149177T3
Authority
ES
Spain
Prior art keywords
thr
ala
peptide
neurosiquiatrically
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92912694T
Other languages
English (en)
Inventor
Thomas Peter Bridge
Frederick K Goodwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2149177T3 publication Critical patent/ES2149177T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN METODO PARA TRATAR EL SINDROME DE CANSANCIO CRONICO NO ASOCIADO CON LA INFECCION DE VIH. EN EL METODO DE LA PRESENTE INVENCION SE ADMINISTRA A LOS PACIENTES UN PORTADOR FARMACEUTICAMENTE ACEPTABLE CON (1) UNA CANTIDAD NEUROSIQUIATRICAMENTE EFECTIVA DE UN PEPTIDO LINEAL DE FORMULA (I): RA-SER-THR-THR-THR-ASN-TYR-R6,DONDE R3 ES ALA, D-ALA O CYS-ALA -AMIDA, O UN DERIVADO DEL PEPTIDO O UNA SAL ACEPTABLE FISIOLOGICAMENTE DE ESTOS; O (2) UNA CANTIDAD NEUROSIQUIATRICAMENTE EFECTIVA DE UN PEPTIDO LINEAL DE FORMULA (II): R1-R2-R3-R4-R5, DONDE R1 ES X-Y O Y CUANDO Y ES THR-, SER-, ASN-, LEU-, ILE-, ARG SN, ARG GLN, LYS O TRP; R4 ES TYR, Y R5 ES Z-Y O Z DONDE Z ES UN AMINOACIDO Y X ES CYS, O UN DERIVADO DEL PEPTIDO O UNA SAL FISIOLOGICAMENTE ACEPTABLE DE ESTE; O (3) UNA CANTIDAD EFECTIVA NEUROSIQUIATRICAMENTE DE UN PEPTIDO LINEAL DE FORMULA (III): RX-R2R3-R4-RY DONDE RX ES ALA-R1, D-ALA-R1 O X-ALA-R1 DONDE Z-R1, R2, R3, R4 SON DEFINIDOS ANTERIORMENTE, Y RY ES THR,THR-AMIDA O THR-CYS, O UN DERIVADO DEL PEPTIDO O UNA SAL FISIOLOGICAMENTE ACEPTABLE DE ESTE.
ES92912694T 1991-05-08 1992-05-08 Composiciones para el tratamiento del sindrome de fatiga cronica. Expired - Lifetime ES2149177T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/696,556 US5189022A (en) 1988-05-27 1991-05-08 Composition for the treatment of chronic fatigue syndrome

Publications (1)

Publication Number Publication Date
ES2149177T3 true ES2149177T3 (es) 2000-11-01

Family

ID=24797555

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92912694T Expired - Lifetime ES2149177T3 (es) 1991-05-08 1992-05-08 Composiciones para el tratamiento del sindrome de fatiga cronica.

Country Status (10)

Country Link
US (1) US5189022A (es)
EP (1) EP0584247B1 (es)
JP (1) JP3215110B2 (es)
AU (1) AU663875B2 (es)
CA (1) CA2102606C (es)
DE (1) DE69231384T2 (es)
DK (1) DK0584247T3 (es)
ES (1) ES2149177T3 (es)
GR (1) GR3034757T3 (es)
WO (1) WO1992019257A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
JPH05262654A (ja) * 1992-03-18 1993-10-12 Kaken Pharmaceut Co Ltd 慢性疲労症候群治療剤
US6011014A (en) * 1992-03-27 2000-01-04 Advanced Immunit, Inc. Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
WO1993020102A1 (en) * 1992-03-27 1993-10-14 Peptide Technology Limited Peptide t and related peptides in the treatment of inflammation, including multiple sclerosis
AU697847B2 (en) * 1993-09-24 1998-10-15 Advanced Immunit, Inc. Method for the treatment or prevention of eczema/dermatitis
US5795858A (en) * 1993-09-24 1998-08-18 Peptide Technology Limited Treatment or prevention of Crohn's disease and/or ulcerative colitis
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5872123A (en) * 1997-02-18 1999-02-16 Lerner; A. Martin Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US6537997B1 (en) 1997-02-18 2003-03-25 A. Martin Lerner Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US6399622B1 (en) 1997-02-18 2002-06-04 A. Martin Lerner Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
CA2616525C (en) * 2005-07-26 2014-06-17 Cms Peptides Patent Holding Company Limited Novel biologically active peptides and their new uses
US20140100238A1 (en) 2012-10-04 2014-04-10 Ohio State University Method of diagnosing and treating epstein barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880626A (en) * 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
US5013739A (en) * 1986-10-07 1991-05-07 Bernard Bihari Method of treating chronic fatigue syndrome using an opiate receptor antagonist
US5063206A (en) * 1988-12-16 1991-11-05 The United States Of Americas As Represented By The Department Of Health And Human Services Compositions having use as treatment of neuropsychiatric deficits
AU620107B2 (en) * 1988-05-27 1992-02-13 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Compositions having use as treatment of psoriasis and neuropsychiatric deficits

Also Published As

Publication number Publication date
GR3034757T3 (en) 2001-02-28
CA2102606A1 (en) 1992-11-09
EP0584247B1 (en) 2000-08-23
CA2102606C (en) 2003-02-11
US5189022A (en) 1993-02-23
AU663875B2 (en) 1995-10-26
JP3215110B2 (ja) 2001-10-02
WO1992019257A1 (en) 1992-11-12
JPH06510749A (ja) 1994-12-01
EP0584247A1 (en) 1994-03-02
AU2015292A (en) 1992-12-21
DK0584247T3 (da) 2000-11-06
DE69231384D1 (de) 2000-09-28
DE69231384T2 (de) 2001-02-01
EP0584247A4 (en) 1994-09-14

Similar Documents

Publication Publication Date Title
ES2149177T3 (es) Composiciones para el tratamiento del sindrome de fatiga cronica.
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
KR960703015A (ko) 후천성 면역결핍증 치료용 약물의 제조시 노나- 및 데카펩타이드의 용도(Use of nona-and decapeptides in the preparation of a durg for the treatment of AIDS)
ES8504110A1 (es) "procedimiento para preparar nonapeptidos y decapeptidos analogos a lhrh"
YU46023B (sh) Postupak za dobijanje novih analoga insulina
ZA926337B (en) Polypeptide analogues having growth hormone releasing activity.
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
KR950701937A (ko) 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체(glucagon-like peptide and insulinotropin derivatives)
ES2058796T3 (es) Aislamiento y elucidacion estructural del depsipeptido citostatico lineal dolastatina 15.
CA2112907C (en) Peptide which abrogates tnf and/or lps toxicity
ES2154686T3 (es) Compuestos de piridazino-quinolina.
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
KR900002801A (ko) 당뇨병 치료용 약학적제제
MY199821A (en) Modified lipidated relaxin b chain peptides and their therapeutic use
DK193887A (da) Peptid med bronchodilartorisk og hypotensiv aktivitet
DE3851455D1 (de) Biologisch wirksame Moleküle.
AU671989B2 (en) Treatment of tropical spastic paresis with peptide T
ATE154037T1 (de) Cyclopeptide
NO178151C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive peptider
EP0346068A3 (en) D-cys6 vasopressin antagonists
YU64192A (sh) Analozi insulina
ES8204713A1 (es) Un procedimiento para aislar un polipeptido purificado
SE9302414D0 (sv) Peptid med oxytocinantagonist-aktivitet
US4081433A (en) D-Nle4 -somatostatin and analogues thereof
EP0356395A3 (de) Flankierende Peptide und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 584247

Country of ref document: ES